This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ / /
/ / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Symptomatic individuals have <1% of normal FXIII6,18, resulting in unstable clot formations with reduced resistance to fibrinolysis18

The initial clot forms and bleeding stops, but bleeding can resume 24-48 hours later6

Wound healing problems have been described in 14% of patients4

It affects all races and genders equally, approximately one person in 1-2 million are affected worldwide7 8

Symptomatic individuals have <1% of normal FXIII6,18, resulting in unstable clot formations with reduced resistance to fibrinolysis18

The initial clot forms and bleeding stops, but bleeding can resume 24-48 hours later6

Wound healing problems have been described in 14% of patients4

It affects all races and genders equally, approximately one person in 1-2 million are affected worldwide7 8

>

1. Carcao M, Altisent C, Castaman G et al. Thromb Haemost 2018;118(3):451-460.

2. Carcao M, Fukutake K, Inbal A et al. Semin Thromb Hemost 2017;43(1):59-68.

3. Dorey E. Nat Biotechnol 2014;32:210.

4. Anwar R and Miloszewski KJ. Br J Haematol 1999;107(3):468-484.

5. Williams M, Will A, Stenmo C et al. Haemophilia 2014;20(1):99-105.

6. Hsieh L and Nugent D. Haemophilia 2008;14(6):1190-1200

7. Odame JE, Chan AK, Wu JK et al. Blood Coagul Fibrinolysis 2014;25(3):199-205.

8. Bolton-Maggs PHB. Treatment of Haemophilia. April 2006. No 39. World Federation of Hemophilia.

9. Inbal A, Oldenburg J, Carcao M et al. Blood 2012;119(22):5111-5117.

10. NovoThirteen® Summary of Product Characteristics.

11. Kerlin BA, Inbal A, Will A et al. J Thromb Haemost 2017;15(8):1601-1606.

 

12. Kerlin B, Brand B, Inbal A et al. J Thromb Haemost 2014;12(12):2038-2043.

13. Brand-Staufer B, Carcao M, Kerlin BA et al. Haemophilia 2015;21(3):380-385.

14. Fibrogammin® Summary of Product Characteristics.

15. Hvitfeldt Poulsen L, Kerlin BA, Castaman G et al. Res Pract Thromb Haemost 2020;4(Suppl 1). Abstract PB1169, ISTH 2020 Congress

16. European Medicines Agency. Guideline on plasma-derived medicinal products. Available at: https://www.ema. europa.eu/en/documents/scientific-guideline/guideline-plasma-derived-medicinal-products_en.pdf [Accessed December 2019].

17. Zanon E, Pasca S, Radu C et al. Haemophilia 2019;25(3):e206-e208.

18. Sharief LAT and Kadir RA. Haemophilia 2013;19(6):e349-e357.